Neurology · Clinical trials
Guillain-Barré Syndrome Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About guillain-barré syndrome — and why its trials are hard
Guillain-Barré syndrome (GBS) is an acute, often post-infectious immune-mediated polyradiculoneuropathy causing rapidly progressive limb weakness and areflexia, frequently with sensory and autonomic involvement; severe cases develop respiratory failure requiring ventilation. Subtypes include acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and axonal forms (AMAN/AMSAN), often linked to Campylobacter jejuni and molecular mimicry with ganglioside antigens; the Miller Fisher variant features ophthalmoplegia, ataxia, and areflexia. Diagnosis rests on clinical course, albuminocytologic dissociation in CSF, and electrodiagnostics. The two proven disease-modifying treatments remain intravenous immunoglobulin (IVIG) and plasma exchange, which are equally effective and not additive; corticosteroids alone are ineffective. Supportive care, respiratory monitoring, and autonomic surveillance are critical. Few new drugs have been approved in decades, but complement-targeted therapies are advancing: the C1q inhibitor ANX005 reported positive pivotal Phase 3 results, while earlier C5 inhibition (eculizumab) gave mixed trial outcomes. Most patients recover, though many retain residual deficits.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Intravenous immunoglobulin (IVIG) ((multiple, e.g., Gamunex)) | standard of care since ~1990s | Acute GBS within ~2 weeks of onset | Multiple RCTs; equivalence to plasma exchange established (e.g., Plasma Exchange/Sandoglobulin GBS Trial) | Improvement in GBS disability (Hughes) grade | Equivalent to plasma exchange; hastens recovery vs supportive care |
| Plasma exchange (plasmapheresis) ((procedure)) | standard of care since 1980s | Acute GBS, especially within 4 weeks of onset | North American and French plasma exchange trials | Time to improvement / disability grade | First proven therapy; shortens time to recovery and ventilation compared with supportive care alone |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in guillain-barré syndrome development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Corticosteroids — Cochrane-reviewed RCTs (oral and IV methylprednisolone) | No significant benefit; not recommended | Corticosteroids alone do not hasten recovery and may delay it; adding IV methylprednisolone to IVIG showed no durable benefit. |
| Eculizumab — JET-GBS (Phase 2, Japan) and related studies | Did not meet key efficacy endpoints for functional recovery | Small C5-inhibitor trials suggested safety and possible signals but failed to establish significant functional benefit, so it was not approved for GBS. |
Choosing the right endpoint
Primary endpoints that matter in guillain-barré syndrome trials
- GBS disability scale (Hughes functional grade) — 0–6 ordinal scale of walking/ventilation status; the classic primary efficacy endpoint.
- Time to independent walking / ventilator-free days — Functional recovery milestones central to trial design and prognosis.
- MRC sum score — Composite muscle strength measure tracking motor recovery.
- Proportion improving ≥1 disability grade at 4 weeks — Common responder definition in acute-treatment trials.
How iNGENū runs guillain-barré syndrome trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Guillain-Barré Syndrome clinical trials — FAQs
Is IVIG or plasma exchange better for GBS?
Do steroids help in GBS?
Are new drugs coming for GBS?
Ready to discuss your guillain-barré syndrome trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal